Biotech Values

[oc631]

Although there are no specific plans to announce yet, GILD’s CSO Norbert Bischofberger strongly believes that an all-oral 3- or 4-drug cocktail will be able to cure HCV in most patients. GILD is discussing in-licensing deals for the components of such a cocktail with multiple parties.

Norbert would better serve GILD's shareholders if he withheld comment until after he signs a deal. GILD is the polar opposite of Roche when it comes to volunteering information.